Wang Yong, Chirgadze Nickolay Y, Briggs Stephen L, Khan Sohaib, Jensen Elwood V, Burris Thomas P
Lilly Research Laboratories, Indianapolis, IN 46285, USA.
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9908-11. doi: 10.1073/pnas.0510596103. Epub 2006 Jun 16.
Evidence is presented that the estrogen antagonist 4-hydroxytamoxifen (HT) can occupy not only the core binding pocket within the ligand-binding domain of estrogen receptor (ER) beta but also a second site on its surface. The crystal structure of the ligand-binding domain (LBD) associated with HT was determined to 2.2 A and revealed two molecules of HT bound to the protein. One was located in the consensus ligand-binding pocket, whereas the other bound to a site that overlaps with the hydrophobic groove of the coactivator recognition surface. Relative to the ERalpha-tamoxifen structure, helix 12 has been displaced from the coactivator recognition surface and occupies a unique position. Although it has been demonstrated that association of the antagonist with the core ligand-binding pocket is sufficient to induce an antagonist ligand-binding domain conformation, this structure suggests that small molecules may directly antagonize receptor-coactivator interactions. These results provide a direct demonstration of two binding sites for HT in ERbeta, as has been previously suggested for ERalpha by using biochemical methods, and represent a crystal structure of a small nonpeptide molecule occupying the coactivator recognition site.
有证据表明,雌激素拮抗剂4-羟基他莫昔芬(HT)不仅能占据雌激素受体(ER)β配体结合域内的核心结合口袋,还能占据其表面的第二个位点。与HT相关的配体结合域(LBD)的晶体结构确定为2.2埃,显示有两个HT分子与该蛋白结合。一个位于共有配体结合口袋中,而另一个则与一个与共激活因子识别表面的疏水凹槽重叠的位点结合。相对于ERα-他莫昔芬结构,螺旋12已从共激活因子识别表面移位并占据独特位置。尽管已证明拮抗剂与核心配体结合口袋的结合足以诱导拮抗剂配体结合域构象,但该结构表明小分子可能直接拮抗受体-共激活因子相互作用。这些结果直接证明了HT在ERβ中有两个结合位点,正如之前通过生化方法对ERα所提出的那样,并且代表了一个占据共激活因子识别位点的小分子非肽分子的晶体结构。